SGP

ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced the appointment of Mike Pinder as vice president, marketing. Mr. Pinder brings over 20 years of commercial launch experience in ophthalmology, focused on building, launching, and evolving significant brands, notably in the buy-and-bill specialty pharma model. At SpyGlass Pharma, he will build and lead the marketing function for the company as it continues to progress the Bimatoprost Drug Pad-IOL System (BIM-IOL System) through Phase 3 clinical trials and towards potential commercialization upon FDA approval. "We are thrilled t

ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma" or "Company"), a late-stage biopharmaceutical company, today announced that members of the executive management team will participate in the following upcoming conferences: Stifel 2026 Virtual Ophthalmology ForumDate: Tuesday, May 26, 2026Time: 2:00 p.m. ETFormat: Fireside Chat Jefferies Global Healthcare ConferenceDate: Thursday, June 4, 2026Time: 2:35 p.m. ETFormat: Fireside Chat Goldman Sachs 47th Annual Global Healthcare ConferenceDate: Wednesday, June 10, 2026Time: 10:40 a.m. ETFormat: Corporate Presentation A live webcast and subsequent replay of each presentation can be ac

ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced that the American Medical Association's (AMA) CPT® (Current Procedural Terminology) Editorial Panel approved a new add-on Category III CPT code for attachment and insertion of intraocular lens prosthesis-mounted drug-eluting implant, based on the application submitted for the Bimatoprost Drug Pad-IOL System (BIM-IOL System), in conjunction with established Category I cataract surgery procedure codes. "The approved Category III CPT code for attachment and insertion of the BIM-IOL System in conjunction with routine cataract surge

10-Q - SpyGlass Pharma, Inc. (0001778922) (Filer)

8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL System (BIM-IOL System), with completion of enrollment expected in 2027.Topline 12-month data from the BIM-IOL System Phase 1/2 trial demonstrated elimination of IOP-lowering topical eye drops for 98% of trial participants and 34% mean intraocular pressure (IOP) reduction from baseline at the intended commercial dose of 78-mcg, and all patients achieving best-corrected distance visual acuity (BCDVA) on par with state-of-the-art monofocal IOLs in the control group at 20/32 or better with a mean BCDVA equivalent to 20/20. Bimatoprost-Drug Ring System (BIM-DRS) first-in-human trial is on track to st

10-K - SpyGlass Pharma, Inc. (0001778922) (Filer)

8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)

Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq.Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System (BIM-IOL System) that demonstrated sustained intraocular pressure (IOP) control, elimination of IOP-lowering eye drops for 97% of trial participants, and improved visual performance, with a favorable safety profile.Phase 3 trials of BIM-IOL System are ongoing, with enrollment underway and full enrollment expected in 2027.Cash, cash equivalents and short-term investments expected to fund planned operations through 2028. ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- S

H.C. Wainwright initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $37.00

8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)

97% of patients who received the BIM-IOL System off all topical IOP-lowering therapy at 12-months100% of BIM-IOL System patients achieved 20/32 or better BCDVA and a mean BCDVA equivalent to 20/20 vision, demonstrating high quality of vision, performance in line with the state-of-the-art IOLs in the control groupOverall safety results were comparable to routine cataract surgery ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today announced positive 12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), for th

ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (NASDAQ:SGP) ("SpyGlass Pharma"), a late-stage biopharmaceutical company, today announced that members of the executive management team will host 1x1 meetings at the Jefferies Biotech on the Bay Summit in Miami Beach, Florida on Wednesday, March 11, 2026. About SpyGlass Pharma SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines. The company's mission is to significantly improve the lives of patients with chronic eye conditions by developing dur

Stifel initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $42.00

Citigroup initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $42.00

Jefferies initiated coverage of SpyGlass Pharma with a rating of Buy and set a new price target of $62.00

Leerink Partners initiated coverage of SpyGlass Pharma with a rating of Outperform and set a new price target of $42.00

SCHEDULE 13G - SpyGlass Pharma, Inc. (0001778922) (Subject)

SCHEDULE 13D - SpyGlass Pharma, Inc. (0001778922) (Subject)

SCHEDULE 13D - SpyGlass Pharma, Inc. (0001778922) (Subject)

SCHEDULE 13D - SpyGlass Pharma, Inc. (0001778922) (Subject)

8-K - SpyGlass Pharma, Inc. (0001778922) (Filer)

4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)

4/A - SpyGlass Pharma, Inc. (0001778922) (Issuer)

4 - SpyGlass Pharma, Inc. (0001778922) (Issuer)